MedTrace Logo

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

NCT06851962 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 504

Last updated 2026-02-23

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:

* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?

Participants will:

* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Conditions

  • Diabetes Mellitus Type 2

Interventions

DRUG

Metformin

Metformin maximum daily dose 2000 mg

DRUG

Dulaglutide

Dulaglutide

DRUG

Semaglutide 1.0 mg

Semaglutide

DRUG

Empagliflozin (BI 10773)

Empagliflozin

DRUG

Canagliflozin

Canagliflozin

DRUG

Dapagliflozin

Dapagliflozin

DRUG

pioglitazone

Pioglitazone

DRUG

Sitagliptin

Sitagliptin

DRUG

Vildagliptin (Galvus)

vildagliptin

DRUG

linagliptin

linagliptin

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • European Union Next Generation

    collaborator UNKNOWN

  • Fundación para la Investigación del Hospital Clínico de Valencia

    lead OTHER

Principal Investigators

  • Sergio Martínez Hervás, Doctor · Hospital Clínico Universitario de Valencia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-26
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06851962 on ClinicalTrials.gov